News Releases
All Releases
View Summary Phase II Clinical Data Presented at SITC Annual Meeting Support Immunotherapeutic Mechanism of Action of Peregrine Pharmaceuticals' Bavituximab in Liver Cancer
Nov 10, 2014
PDF 21.0 KB Add to Briefcase
View Summary Data to Be Presented at the SITC Annual Meeting Support Synergy of PS-Targeting and Anti-CTLA-4 Immunotherapies to Enhance Anti-Tumor Treatments in Melanoma
Nov 7, 2014
PDF 56.6 KB Add to Briefcase
View Summary Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From an Investigator-Sponsored Trial of Peregrine Pharmaceuticals' Bavituximab in Combination With Pemetrexed and Carboplatin in Front-Line Non-Small Cell Lung Cancer
Oct 30, 2014
PDF 69.2 KB Add to Briefcase
View Summary Data to Be Published in the Journal of Immunology Research Support Phosphatidylserine (PS) as a Potential Target in Ebola Infection
Oct 15, 2014
PDF 22.1 KB Add to Briefcase
View Summary Data to Be Presented at CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Decreasing Levels of Myeloid Derived Suppressor Cells (MDSC) in the Tumor Microenvironment
Oct 6, 2014
PDF 19.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results and Recent Developments
Sep 9, 2014
PDF 31.1 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Sep 8, 2014
PDF 13.7 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015 Financial Results After Market Close on September 9, 2014
Sep 2, 2014
PDF 14.3 KB Add to Briefcase
View Summary Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression
Aug 11, 2014
PDF 20.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2014 Financial Results and Recent Developments
Jul 14, 2014
PDF 34.4 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End Fiscal 2014 Financial Results After Market on July 14, 2014
Jul 7, 2014
PDF 14.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Jun 10, 2014
PDF 13.6 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy®) in Advanced Melanoma
Apr 23, 2014
PDF 22.8 KB Add to Briefcase
View Summary Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer
Apr 9, 2014
PDF 22.7 KB Add to Briefcase
View Summary Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung Cancer
Apr 7, 2014
PDF 19.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting
Apr 1, 2014
PDF 16.0 KB Add to Briefcase
View Summary Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase l/ll Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer
Mar 14, 2014
PDF 18.2 KB Add to Briefcase
View Summary Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies
Mar 13, 2014
PDF 56.2 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Mar 11, 2014
PDF 13.1 KB Add to Briefcase
View Summary Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies
Mar 11, 2014
PDF 20.1 KB Add to Briefcase
Showing 1-20 of 549 Page: 1 2 3 4 5 ... 28  Next 20
Add to Briefcase = add release to Briefcase
Print E-mail